Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer.

Next Previous
Trial Profile

A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LY 3007113 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 15 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
  • 12 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 08 Mar 2013 Planned number of patients changed from 85 to 36 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top